Biopharma | May 08, 2026
Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Arcot is a seasoned executive with more than two decades of experience across the global pharma and life sciences sectors
Nature Medicine study delivers strongest real-world evidence yet for India’s indigenous rotavirus vaccine under UIP
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
